Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials

[1]  Trung Nghia Tran,et al.  Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy , 2022, Journal of asthma and allergy.

[2]  T. Hill,et al.  Assessment of real-world escalation to biologics in US patients with asthma. , 2022, Journal of Allergy and Clinical Immunology: In Practice.

[3]  Todor A Popov,et al.  Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. , 2022, The journal of allergy and clinical immunology. In practice.

[4]  E. Bel,et al.  Long-term therapy response to anti-interleukin-5 biologics in severe asthma - a real-life evaluation. , 2020, Journal of Allergy and Clinical Immunology: In Practice.

[5]  T. Tay,et al.  Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.

[6]  L. Boulet,et al.  Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena , 2020, European Respiratory Journal.

[7]  Richard D Riley,et al.  Calculating the sample size required for developing a clinical prediction model , 2020, BMJ.

[8]  C. Jenkins,et al.  Mepolizumab effectiveness and identification of super-responders in severe asthma , 2020, European Respiratory Journal.

[9]  Ewout W Steyerberg,et al.  Models with interactions overestimated heterogeneity of treatment effects and were prone to treatment mistargeting. , 2019, Journal of clinical epidemiology.

[10]  D. Sin,et al.  Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study , 2019, Thorax.

[11]  J. Stratil,et al.  Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990–2017 , 2019, BMJ Global Health.

[12]  G. A. Whitmore,et al.  "Placebo Effects" in Clinical Trials Evaluating Patients with Uncontrolled Persistent Asthma. , 2019, Annals of the American Thoracic Society.

[13]  S. Szefler,et al.  Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  J. Corren,et al.  Tezepelumab in Adults with Uncontrolled Asthma. , 2019, The New England journal of medicine.

[15]  Ewout Steyerberg,et al.  Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects , 2018, British Medical Journal.

[16]  C. Bennett,et al.  Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition , 2018, Drugs.

[17]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[18]  R. Olivenstein,et al.  Asthma biomarkers in the age of biologics , 2017, Allergy, Asthma & Clinical Immunology.

[19]  I. Abraham,et al.  "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. , 2017, The journal of allergy and clinical immunology. In practice.

[20]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[21]  R. Chaudhuri,et al.  Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study) , 2016, BMJ Open.

[22]  A. Zwinderman,et al.  The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.

[23]  C. Porsbjerg,et al.  The prevalence of severe asthma and low asthma control among Danish adults. , 2014, The journal of allergy and clinical immunology. In practice.

[24]  O. Norheim,et al.  A three-stage approach to measuring health inequalities and inequities , 2014, International Journal for Equity in Health.

[25]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[26]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[27]  Xiaoni Zhong,et al.  Methods for measuring horizontal equity in health resource allocation: a comparative study , 2014, Health Economics Review.

[28]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[29]  I. Pavord,et al.  EAACI position statement on asthma exacerbations and severe asthma , 2013, Allergy.

[30]  P. Austin,et al.  Using G-Computation to Estimate the Effect of Regionalization of Surgical Services on the Absolute Reduction in the Occurrence of Adverse Patient Outcomes , 2013, Medical care.

[31]  M. Lokshin,et al.  A Unified Approach to Measuring Poverty and Inequality: Theory and Practice , 2013 .

[32]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[33]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[34]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[35]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[36]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[37]  C. Bucca,et al.  Asthma severity and medical resource utilisation , 2004, European Respiratory Journal.

[38]  R. Stott,et al.  The World Bank , 2008, Annals of tropical medicine and parasitology.

[39]  J. Gastwirth.  The Estimation of the Lorenz Curve and Gini Index , 1972 .